A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
incidence and severity of ocular adverse events and systemic adverse events
12 months and 24 months after initial treatment
Yes
Ivana Kim, M.D.
Principal Investigator
Massachusetts Eye and Ear Infirmary
United States: Food and Drug Administration
07-06-040
NCT00765921
June 2008
December 2013
Name | Location |
---|---|
Massachusetts Eye & Ear Infirmary | Boston, Massachusetts 02114 |